RYTM — Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $57.3 million, a 12% increase from Q3 2025 and a 37% increase year-over-year.
• Full Year 2025 Revenue: $194.8 million, up approximately 50% from 2024.
• U.S. Revenue: $39 million (68% of total); Ex-U.S. Revenue: $18.3 million (32% of total).
• Gross to Net for U.S. Sales: Approximately 84.6%.
• Cost of Goods Sold (COGS): 8.5% of product revenue, down slightly due to increased finished goods inventory.
• R&D Expenses: $42 million for Q4, slightly up from $41.2 million year-over-year.
• SG&A Expenses: $57.5 million for Q4, up from $38.1 million in Q4 2024, reflecting increased headcount and launch preparations.
• Net Loss per Share: $0.73, including $0.02 from accrued dividends on convertible preferred stock.
• Cash Position: Approximately $389 million, expected to fund operations for at least 24 months.

2. Strategic Updates and Business Highlights

• Bivamelagon HO Study: Positive end-of-phase 2 meeting with the FDA; plans to initiate phase 3 study by year-end 2026, requiring a 12-month trial with a larger patient cohort.
• IMCIVREE Launch Preparation: Focus on Acquired Hypothalamic Obesity (HO) with a PDUFA date set for March 20, 2026. Sales force expanded from 16 to 42 to support the launch.
• International Expansion: IMCIVREE now available in over 25 countries, with significant growth in Europe and ongoing early access programs in France and Italy.
• Patient Engagement: Increased efforts to educate healthcare providers and secure reimbursement for Acquired HO, identifying over 2,000 patients.

3. Forward Guidance and Outlook

• 2026 Non-GAAP Operating Expenses: Expected to be between $385 million and $415 million, driven by increased spending on clinical programs and commercial operations.
• Anticipated Milestones: Upcoming data releases and regulatory submissions, including top-line data from the Japanese HO cohort and the M&A readout in March 2026.

4. Bad News, Challenges, or Points of Concern

• Inventory Management: Increased inventory days on hand, indicating potential pull-forward of revenue from Q4 to Q1 2026, which may dampen Q1 sales.
• Regulatory Challenges: FDA's requirement for a full 12-month phase 3 trial for bivamelagon may extend timelines and increase costs.
• Market Competition: The presence of other obesity treatments, such as GLP-1s, may impact market penetration and patient adoption rates.

5. Notable Q&A Insights

• Bivamelagon Phase 3 Trial: Expected to mirror the design of the setmelanotide trial, with no major changes in enrollment criteria anticipated.
• Acquired HO Patient Identification: Ongoing efforts to refine patient identification processes, with confidence in the potential patient population exceeding previous estimates.
• Regulatory Strategy for EMANATE: Plans to submit individual sNDAs for each genetic indication rather than a combined submission.
• Dosing Strategy for Bivamelagon: Target dose for phase 3 will be 600 mg, with potential for patients to respond positively over time.

Overall, Rhythm Pharmaceuticals demonstrated strong financial growth in 2025, with significant strategic initiatives underway to expand its product offerings and market presence, despite facing regulatory hurdles and competitive pressures in the obesity treatment landscape.